Global Supply Chain
-
Drug Stocks Are Starting To Trade Their Factory Maps, Not Just Their Pipelines
A fresh U.S. tariff clock, Roche’s June 4 backlash, Takeda’s global manufacturing footprint and Samsung Biologics’ new Maryland site all point to the same message: in pharma, location is becoming a market variable again.
-
Rare-Earth Magnets Are Becoming a Real Trading Theme Again: South Carolina, France, Japan and Korea Are Now in the Same Story
Fresh U.S. and European magnet-factory spending has turned rare earths back into a live trading narrative, but the real signal is that Japan and Korea still see the bottleneck as a threat to chips, industrials and pricing power.